NovoCure NVCR Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by NovoCure in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.
The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about NovoCure's change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NovoCure's change in accrued liabilities?
- NovoCure (NVCR) reported change in accrued liabilities of -$219K in Q1 2026.
- How has NovoCure's change in accrued liabilities changed year-over-year?
- NovoCure's change in accrued liabilities increased by 90.4% year-over-year, from -$2.27M to -$219K.
- What is the long-term trend for NovoCure's change in accrued liabilities?
- Over 4 years (2021 to 2025), NovoCure's change in accrued liabilities has grown at a 169.4% compound annual growth rate (CAGR), from -$94K to $4.95M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.